aTyr Pharma cuts workforce 60% to focus on efzofitimod in lung disease
The company is awaiting FDA feedback by late August 2026 on its planned Phase 3 pulmonary sarcoidosis trial while restructuring to preserve cash into late 2028.
SEC filing
Latest
2 stories
Friday, August 7
Friday, July 31
aTyr and Kyorin sign termination agreement, ending Japan efzofitimod deal
The July 30, 2026 agreement ends Kyorin's license and hands aTyr full rights to develop and commercialize efzofitimod worldwide.
SEC filing